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Abstract 
This European Respiratory Society statement provides a comprehensive overview on 
protracted bacterial bronchitis (PBB) in children. A Task Force of experts, consisting of 
clinicians from Europe and Australia who manage children with PBB, determined the overall 
scope of this statement through consensus. Systematic reviews addressing key questions were 
undertaken, diagrams in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement constructed and findings of relevant 
studies summarised. The final content of this Statement was agreed upon by all members.  
 
The current knowledge regarding PBB is presented, including the definition, microbiology 
data, known pathobiology, bronchoalveolar lavage findings, and treatment strategies to 
manage these children. Evidence for the definition of PBB was sought specifically and 
presented. Also, the Task Force identified several major clinical areas in PBB requiring 
further research, including collecting more prospective data to better identify the disease 
burden within the community, determining its natural history, a better understanding of the 
underlying disease mechanisms, and how to optimise its treatment with a particular 
requirement for randomised controlled trials to be conducted in primary care. 
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Case vignette 
A 3 year old boy attends your clinic with his mother who is concerned about his persistent 
cough and ‘rattly breathing’ that have both been present and unrelenting over the last 6-
weeks. Upon history taking, you learn that his symptoms were accompanied initially by a 
low-grade fever and nasal discharge, and while these resolved in 2 and 7-days respectively, 
his cough persisted. You identify that the cough is wet in nature. He is well grown, fully 
immunised and has no history of aspiration or recurrent sino-pulmonary infections. There is 
no family history of chronic pulmonary disease, but the father smokes cigarettes outside the 
home. The child attends childcare. You confirm on examination the presence of a 
spontaneous wet cough. There are no signs of upper airway infection and no other abnormal 
physical findings are present. The chest radiograph shows only perihilar changes.  
 
You consider that this child most likely has protracted bacterial bronchitis (PBB). What is the 
evidence for the existence of PBB? How is it diagnosed and managed? What is its prognosis? 
What are the causes and risk factors and how can it be prevented?  
 
Introduction 
Cough is the most common presenting symptom in those seeking primary health care.[1] 
Within this large group of patients are children similar to the child described in the case 
vignette by having a chronic (>4-weeks) cough where there may be considerable, but often 
unrecognised, morbidity adversely impacting upon their quality of life (QoL).[2,3] Amongst 
children referred to a specialist respiratory clinic because of a chronic cough, more than 80% 
had sought medical advice on five or more occasions during the preceding 12-months and 
53% had been taken to the doctor more than ten times during the same period.[2]  
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Protracted bacterial bronchitis (PBB) is characterised by an isolated chronic wet or 
productive cough without signs of another cause and usually responds to 2-weeks of an 
appropriate oral antibiotic.  The term was first described as a diagnostic entity by the group 
from Brisbane in 2006[4] and also recognised then in guidelines as a cause of chronic wet 
cough in children.[5,6] Although the true prevalence of PBB within the community is 
unknown, single and multi-centre studies from Australia[4,7] and Turkey[8,9] diagnosed 
PBB in 11-41% of children referred to specialist respiratory clinics where it was found to be 
one of the most common causes of chronic cough.   
 
PBB is not a new entity and PBB-like conditions were being reported during the last 
century.[10] In the 1940s the possibility of a link between chronic bronchitis and 
bronchiectasis was raised,[11] including suggestions that this could be interrupted by 
intensive antibiotic therapy.[11,12] Later in the 1980s, a retrospective review of 20 children 
with chronic bronchitis reported bronchoscopic evidence of bronchial wall inflammation, 
purulent bronchial secretions, containing mainly Haemophilus influenzae, and most improved 
following antibiotic therapy.[13] This report coincided with publication of Cole’s ‘vicious 
circle’ hypothesis of chronic bacterial infection and inflammation causing bronchiectasis,[14] 
which helped to provide a conceptual framework for PBB as a potential pre-bronchiectasis 
state in some children.[15]   
 
PBB is often misdiagnosed as asthma, resulting in inappropriate and often high doses of 
inhaled corticosteroids.[7,16] Generic health-related (PedsQoL[17]) and chronic cough-
specific (PC-QoL) QoL scores of children with PBB were found to be similar to those 
recorded in children from other diagnostic groups (asthma, bronchiectasis, those whose 
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chronic cough resolved without treatment) when the QOL measures were undertaken at the 
first presentation to respiratory specialists,[7,18] but normalised when the cough resolved.[7]  
 
Thus, while PBB-like descriptions are certainly not new with the clinical features being well 
described in previous decades, it is now a distinct diagnostic entity and our knowledge of the 
clinical and pathobiological features has progressed rapidly in recent years. However, as 
studies of PBB have relied upon children presenting to hospital and specialist clinics, our 
understanding of the true underlying epidemiology and disease burden of PBB is limited by 
the absence of community data. This European Respiratory Society Taskforce position 
statement on PBB outlines current knowledge and provides a clinical profile, diagnostic 
indications and a therapeutic approach to this common disease in children. It also highlights 
areas of future research. 
 
Methodology 
The European Respiratory Society (ERS) PBB taskforce team consisted of 11 members 
(general paediatricians, respiratory and infectious disease specialists) representing clinicians 
in Europe and Australia managing children with chronic cough. ERS standardised procedures 
for conflict of interest declaration were followed. The key questions (KQ), framed in a 
Patient Intervention Comparison Outcome (PICO) format, were developed by the group and 
distributed among four pairs of authors (Supplementary File 1). Author pairs undertook the 
systematic reviews based on the method used in the paediatric sections of the American 
College of Chest Physicians (ACCP) CHEST cough guidelines[19,20] and the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement 
(Supplementary Figures). 
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The KQs (all related to children aged <18-years) 
1. In children with chronic (>4-weeks) wet or productive cough unrelated to an underlying 
disease and without any specific cough pointers (see Box);  
a. what is the evidence for PBB in clinical studies and clinical guidelines? 
b. what symptoms (including cough duration) and signs are used to diagnose PBB? 
2. In children with chronic (>4-weeks) wet or productive cough without any specific cough 
pointers, what: 
a. are the possible causes? 
b. tests should be undertaken and when should they be referred for further 
investigations? 
c. is the risk of harm in cases of delayed treatment and investigations? 
3. In children with chronic (>4-weeks) wet or productive cough  unrelated to an underlying 
disease and without any specific cough pointers, what bacteria are cultured from the 
lower airways? 
4. In children with PBB, in addition to ‘classical’ bacteriology, what else is known about the 
airway microbiology (viruses, virus-bacteria interactions, microbiome)? 
5. In children with PBB, what is known about its pathobiology (risk factors, underlying 
mechanisms, cellular pathways, immunity and airway malacia,)?  
6. In children with chronic (>4-weeks) wet or productive cough unrelated to an underlying 
disease and without any specific cough pointers; 
a. How effective are antibiotics at improving clinical outcomes (eg. cough resolution)? 
b. What is the most suitable antibiotic? 
c. For how long should antibiotics be prescribed? 
d. Does treatment dose and duration influence risk of recurrence in the following  
12-months? 
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7. In children with chronic (>4-weeks) wet or productive cough unrelated to an underlying 
disease and without any specific cough pointers;  
a. What is the role of prophylactic antibiotics? 
b. What is the risk of antibiotic resistance? 
c. How should recurrences be managed? 
 
Searches, data extraction and summaries 
Searches relating to the KQs were undertaken by 4 pairs of the taskforce members whereby 
one member of each reviewer pair used a standard format (Supplementary File 1) based on 
the ACCP’s CHEST cough pediatric guidelines.[19,20] Both reviewers within each pair 
independently reviewed all abstracts and agreed upon which full-text articles to retrieve to 
assess for potentially eligible studies. It was decided that disagreements unable to be resolved 
by consensus would be adjudicated by a third reviewer (AK). As there were no new 
randomised controlled trials (RCTs) following the published systematic review on chronic 
wet cough in children,[20] risk of bias criteria was not undertaken. For cohort studies, data 
were extracted by a single reviewer and checked by another reviewer. In cohort studies, we 
reported on the study’s setting, number enrolled and completing the study, inclusion and 
exclusion criteria, and main results relating to the respective KQs. 
 
Summaries of the data relating to each KQ were presented to the entire group at a face-to-
face meeting in April, 2016. Following a review of the data and discussions, this document 
and statements were formulated. Consensus was defined a-priori as agreement by >80% of 
the group. Key findings from the KQs and Task Force statements are presented below with 
additional details presented in the Supplementary Files. Studies had components common to 
almost all the KQs and they are summarised in the Table.  
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Definition of PBB (KQ1) 
As outlined recently,[21] the Task Force recommends that for day-to-day clinical practice, 
PBB is considered present when all  three criteria listed below are fulfilled: 
i. Presence of continuous chronic (>4-weeks duration) wet or productive cough  
ii. Absence of symptoms or signs (ie. specific cough pointers) suggestive of other causes 
of wet or productive cough (see Box) and 
iii. Cough resolved following a 2-4 week course of an appropriate oral antibiotic.  
 
The evidence for PBB in clinical studies and guidelines (KQ1) 
The validity of each criterion was outlined in a recent review[21] and updated in this 
systematic review for duration of cough, in the absence of other symptoms and signs 
(Supplementary Tables 1.1a-b). The Task Force chose the 4-week diagnostic threshold based 
upon the inclusion criteria of the studies outlined in the Supplementary Tables 1.1a-b. Other 
than the British Thoracic Society guidelines, all other national guidelines use a cough 
duration >4-weeks. However, the duration of cough may need adjusting if new data arise 
from prospective, longitudinal observational studies recommended by the ACCP cough 
guidelines.[20] Such information is especially required from within the primary health care 
setting.  
 
In prospective studies that are currently available (Supplementary Table 1.1a), the mean or 
median duration of cough (at presentation) varied from 3-weeks[22] to as long as  
6-months.[4] The lowest first quartile was 4-weeks and lowest 95th% percentile was  
2.6-months. In the retrospective studies (Supplementary Table 1.1b), the mean or median 
cough duration varied from 10-weeks[23] to 11-months.[24] The lowest range value was 1-
month[25] and lowest 95% percentile was 9.6-weeks.[23]  
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PBB as a diagnostic entity and cause of wet cough was well-documented in prospective and 
retrospective studies (Supplementary Tables 1.1a-b). The response to oral antibiotics was 
used to help define PBB in almost all studies and national cough guidelines in children. 
However, the length of antibiotic courses to define PBB varied between studies. In all but 
one of the prospective studies, the duration of antibiotic treatment ranged from 10-days to  
2-weeks (Supplementary Table 1.1a). However, in the retrospective studies, the mean 
duration of antibiotic courses either varied from 17-days to 6-8 weeks or was unspecified 
(Supplementary Table 1.1b).  
 
Prospective studies were also supported by other descriptive studies examining the associated 
bacteriology, inflammatory profiles, and immune responses, providing further evidence of 
PBB as a diagnostic entity in children (Supplementary Tables 1.3a-b). While an adult version 
of PBB has not been clearly described, it has been suggested by some clinicians.[26] 
However, in this particular report,[26] other than presence of wet or productive cough, other 
criteria such as duration of cough went undefined. Furthermore, another adult case series[27] 
described chronic productive cough unrelated to bronchiectasis, which responded only to 
intravenous antibiotics. This requirement for parenteral antibiotics however, is used to help to 
differentiate between chronic suppuratives lung disease (CSLD) and PBB in children.[15] 
 
Despite all national society chronic cough guidelines describing PBB as a cause of chronic 
wet cough, variations in the definition of PBB between them still exist (Supplementary Table 
1.2). 
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Typical profile child with PBB (KQ1) 
Part of KQ1 also reviewed what symptoms and signs (other than wet cough) were used (or 
found) in descriptions of children with PBB. The prospective studies (Supplement Table 
1.3a) specified that no other symptoms (other than wet cough) or signs were present, 
although some had ‘parent reported wheeze’. The retrospective studies (Supplement Table 
1.3b) commonly described wheeze or ‘noisy breathing’ being present. Concomitant 
bronchodilator responsiveness was also described in some studies, and was particularly 
common in one retrospective study (9 of 20 children,[13]) although this high proportion 
could have been from patient selection.  
 
As summarised previously,[21] while children with PBB were typically young (mean or 
median age 1.8-4.8 years), PBB was also recognised in older (age >12-years) 
children.[7,28,29] Most children with PBB lacked systemic symptoms without evidence of 
sinusitis or ear disease.[4,30] Compared to ‘disease controls’ undergoing bronchoscopy for 
non-cough-related indications (eg. stridor or apnoea), children with PBB were more likely to 
have attended childcare (odds ratio (OR)=8.4, 95% confidence interval (CI) 2.3-30.5), but 
their tobacco smoke exposure (~30%[4,30]) was similar to that of the ‘controls’.[30] 
Children with PBB typically appeared well. They had normal growth and development, and 
lacked signs of underlying CSLD, such as digital clubbing, chest wall deformity or 
adventitial auscultatory chest findings,[30] although occasionally a ‘rattly chest’ and crackles 
were heard.  
 
The prevalence of atopic features (eczema, systemic and airway eosinophilia, elevated IgE or 
positive radioallergosorbent test) was similar to children without PBB.[30] While many 
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parents reported previous ‘ever wheeze’ (41-81%[16,30]), auscultation-confirmed wheeze by 
doctors was unusual.  
 
The chest radiograph was normal or near-normal, showing only peri-bronchial 
changes.[15,31,32] When performed, both spirometry[31] and respiratory system reactance 
and resistance measured by the forced oscillatory technique (unpublished) were also normal. 
While no RCTs have assessed whether ordering chest radiographs and/or spirometry in 
children with PBB or chronic wet cough enhanced management, a systematic review found  
‘high-quality’ evidence for improved clinical outcomes by adopting cough management 
protocols (or algorithms) in children with chronic cough aged <14-years.[19] Steps in these 
cough management algorithms included undertaking a chest radiograph and (when possible) 
spirometry.[19] When an abnormality in either the spirometry and/or the chest radiograph  
(other than peri-bronchial changes) in a child with chronic wet cough is present, additional 
investigations for an underlying cause are indicated (see Figure). PBB may co-exist with 
other diseases, (e.g. asthma and airway malacia); although for asthma studies including 
objective assessments of reversible airflow limitation to help determine whether there is any 
association have not been undertaken. 
 
Other causes of chronic wet cough in children (KQ2) 
Data from KQ2 included evaluating causes of chronic wet or productive cough in children 
when they first present to doctors (Supplementary Tables 2.1). These other causes of chronic 
wet cough in children include, but are not limited to: pertussis, tuberculosis, inhaled foreign 
body, bronchiectasis, cystic fibrosis (CF), aspiration or congenital lung lesions. Most 
however have other symptoms and signs present (i.e. cough pointers[19,31,32]). 
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KQ2 also addressed other investigations and the possible harm from having a prolonged wet 
cough (Supplementary Tables 2.2-2.3). Data suggest that children should be referred for 
further investigations when specific cough pointers (see Box) are present or when the wet 
cough does not respond to 4-weeks of antibiotics. One study found that failure of the cough 
to respond to 4-weeks of antibiotics increased the chance of bronchiectasis being present 
(adjusted OR=20.9, 95%CI 5.4, 81.8).[33] Another study reported the duration of chronic 
wet cough was significantly associated with increased risk of structural airway abnormalities 
and increased Bhalla scores on chest computed tomography (CT) scans.[34]    
 
Microbiology (KQ3 and KQ4) 
Wet cough (KQ3)  
The respiratory bacterial pathogens found in studies of chronic wet cough are summarised in 
Supplementary Table 3.1. H. influenzae was overall the most common organism found in  
28-58% of children,[4,29,35,36,37,38] with Streptococcus pneumoniae (13-58%) and 
Moraxella catarrhalis (17-59%) the two other most frequently detected organisms. These 
results are similar to findings in PBB (Supplementary Table 3.2). 
 
PBB (KQ3) 
The first study describing PBB detected commonly recognised respiratory pathogens  
(H. influenzae (47%), S. pneumoniae (35%) and M. catarrhalis (26%)) in BAL cultures at 
high bacterial loads (>105 colony-forming units/mL).[4] Subsequently, other studies have 
supported these findings (Supplementary Table 3.2). As in children with chronic wet cough, 
H. influenzae was the most common pathogen (38-81%) cultured from children with PBB. 
Although most H. influenzae are likely to be non-typeable (NTHi) strains, only two studies 
have attempted capsular typing of H. influenzae isolates.[28,39] The other commonly 
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detected bacteria are S. pneumoniae (16-39%) and M. catarrhalis (19-51%), while 
Staphylococcus aureus has been found (6-22%) in five of the ten published studies 
(Supplementary Table 3.2).  Differences in the types of S. pneumoniae serotypes encountered 
in children with PBB from different countries have been reported and may have arisen from 
variations in antibiotic prescribing and vaccine practices. For example, in one comparative 
study, 100% of S. pneumoniae isolates from Greek children undergoing BAL for PBB were 
serotypes contained in the 13-valent pneumococcal conjugate vaccine, while only 28% of  
S. pneumoniae isolates in BAL cultures from fully vaccinated English children with PBB 
were vaccine-type serotypes.[28] Finally, polymicrobial infections involving multiple 
respiratory bacterial pathogens were identified in the lower airways of 30-50% of affected 
children.[16,24,28,38,40]  
When assessing the bacteriology of PBB it is important to note that not all BAL studies are 
directly comparable with one another as only some utilised quantitative bacterial culture to 
describe BAL findings.[28,40] The distribution of bacteria within the lungs is not uniform. 
One retrospective study reported that sampling from a single lobe would have missed 17 
different organisms in 15/50 patients, eight of whom would not have had any organisms 
cultured.[40] Nonetheless it should be noted that this study used non-quantitative bacterial 
culture methods and failed to not report bacterial densities between the various lobes. A 
summary of information on bacteria found in PBB is presented in Supplementary Table 3.2. 
 
Viruses (KQ4) 
Our systematic review (Supplementary Table 4.1) revealed 2 studies that reported on viruses 
in children with PBB[30,41] and another in children with wet cough.[38] However, only 
single study that specifically systematically examined for viruses.[30] The presence of any 
virus was found in 38% of BAL samples from 104 children with PBB,[30] which was 
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significantly greater than in 49 children with other chronic respiratory disorders (38% vs 9%; 
OR=6.3, 95%CI 2.1-19.1). The most common virus detected in children with PBB was 
human adenovirus (HAdV) (23%) of which most were representatives of the HAdV-C 
species (detected in 96% of HAdV+ children).[41] An extended molecular-based diagnostic 
panel for 17 respiratory viruses was performed in a subset of 27 children, which found 
rhinovirus in 11 (41%) subjects and human bocavirus and human coronavirus in one (4%) 
each of the participants.[30] However, the prevalence of these other viruses was similar in 
the control group.[30] The same study showed that lower airway infection with H. influenzae 
(>104 CFU/mL) was significantly associated with HAdV co-infection.[30]  
 
Microbiota (KQ4) 
Our systematic review identified a single study that examined the lower airway microbiota of 
children with PBB.[42] It compared the microbiota of 12 children with PBB with that of 19 
children with bronchiectasis and 25 with CF.[42] Unlike adult studies, where significant 
inter-individual differences exist in bacterial community composition between patients with 
CF and bronchiectasis, the core microbiota in the three aforementioned conditions was 
similar during early childhood with H. influenzae and oral aerobic (S. mitis) and anaerobic 
(Prevotella melaninogenica) commensals the most commonly shared core species. 
Subsequent to our systematic review, a larger study involving 78 children (PBB=28, 
CSLD/bronchiectasis=40, disease controls=10), found that the microbiota in upper and lower  
airways helped to discriminate between these clinically defined groups.[43] Employing 
PERMANOVA, a type of multivariate analysis of variance using distance measurements, 
significant differences in the lower airway microbiota (core and satellite combined) between 
the disease groups (p = 0.0001) were found and diagnostic groups accounted for 29.2% of the 
total variation in the microbiota.[43] 
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Pathobiology (KQ5) 
Risk factors (KQ5) 
Besides microbiology, the pathobiology of PBB (addressed in KQ5 and summarised in 
Supplementary Tables 5.1-5.2) involves risk factors, underlying structural airway lesions, 
and host airway inflammatory and immune responses. However, few studies have described 
PBB risk factors and these report a male predominance[23,38] and a median age of 10-31 
months.[4,23,38] In addition, a single prospective study found childcare attendance was the 
single positive risk factor in 91% of PBB cases compared with 58% of disease controls.[30] 
 
Airway Inflammation (KQ5) 
Studies included in the systematic review describing the BAL inflammatory profile of PBB 
had similar findings of intense airway neutrophilia (summarised in Supplementary 5.1a and 
5.1b), with a percentage neutrophil median range of 25.5-44%.[4,16,44,45,46,47] The airway 
neutrophilia was accompanied by a raised total cell count with a median range of 188-426 x 
106/L.[4,44,45,46,47,48] No airway eosinophilia was observed in any study and a single 
study described an increase in the percentage of lymphocytes.[46]  
 
An associated marked inflammatory mediator response was also found in the BAL fluid of 
children with PBB. Increased levels of interleukin (IL)-8, matrix metalloproteinase (MMP)-9 
active and IL-1 correlated with the degree of neutrophilia.[44,45,49] Other pro-
inflammatory mediators detected at increased levels in the BAL fluid of PBB patients 
included -defensin, IL-1 pathway cytokines, and CXCR2 gene and protein 
expression.[46,49,50] Also, IL-1beta and related mediators were associated with BAL 
neutrophils, cough symptoms and disease recurrence.[46] 
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Immunity (KQ5) 
Studies outlined in Supplementary Table 5.1b consistently demonstrate that children with 
PBB have preserved systemic adaptive immunity with normal serum immunoglobulin levels 
(IgA, IgM, IgG and IgE) and normal antibody-mediated responses to both protein (tetanus) 
and conjugated protein-polysaccharide based (H. influenzae type b) vaccines.[4,30] 
Lymphocyte subset were also normal, except for increased CD56 and CD16 natural killer 
cell levels for age.[23,30]  
 
Several studies described activated pulmonary innate immune pathways.[23,30,45,47,50] 
Specifically, the toll-like receptors (TRLs) associated with bacterial infection (TLR-2 and -4) 
were elevated in PBB. Another study reported augmented human -defensin 2 (hBD2) and 
mannose-binding lectin (MBL) levels, while activated caspase-1 dependent pro-inflammatory 
pathways in response to NTHi were also detected in children with PBB, indicating that both 
innate pathogen recognition and clearance mechanisms were intact.[47]  
 
Finally, a recent study of BAL fluid samples from children with PBB discovered reduced 
alveolar macrophage phagocytic host responses to NTHi and to apoptotic cells (ie. deficient 
efferocytosis).[44] It is therefore possible that the combination of reduced efferocytosis and 
increased IL-1β pathways could lead to persistence of the activated M1 macrophage 
phenotype with its pro-inflammatory effects and resulting chronic neutrophilic airway 
inflammation.[44] Efferocytosis values in children with PBB were in between controls and 
children with bronchiectasis.[44] 
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Bronchoscopic findings (KQ5) 
Purulent airway secretions and large airway malacia are common bronchoscopic findings in 
children with PBB.[15,21,37] Studies seeking specifically both PBB and tracheo-
bronchomalacia reported airway malacia in 74% of PBB cases in one retrospective study[25] 
and 68% in a prospective study,[30] although in the latter 53% of disease controls also had 
evidence of airway malacia.[30] Systematic review of available studies shows it remains 
unclear whether one condition is an antecedent of the other. Whilst the reduced airway 
clearance found in tracheo-bronchomalacia is thought to predispose to PBB, it is also 
possible that chronic infection and airway inflammation leads to secondary airway malacia 
developing.[51] A recent study comparing clinical findings, airway cellularity and bacterial 
cultures in PBB patients with and without tracheo-bronchomalacia observed no differences 
between the two groups.[23] Hence, although a common finding, the role of airway malacia 
in the pathobiology of PBB remains largely unknown. 
 
Therapy (KQs 6) 
Thirteen studies were included in the systematic review for KQ6 and the primary studies are 
summarised in Supplementary Table 6. One was a Cochrane review,[52] three were 
RCTs,[22,48,53] while the remaining nine were descriptive studies, of which four involved 
prospective cohorts of children with a chronic cough[4,8,9,29] and five were retrospective 
reviews.[13,16,24,25,33]  
 
The three RCTs[22,48,53] were the only studies whose principal aims were to determine the 
efficacy of antibiotics in resolving a chronic wet cough in young children. The Cochrane 
review included two of these studies, one of which was open-labelled,[22] and when both 
were combined they involved 140 children <7-years of age.[31,53] While concluding that 
19 
antibiotics were likely to be beneficial (pooled OR 0.13 (95%CI 0.06, 0.32) for children with 
persistent cough post-treatment), the review also raised concerns over study quality and 
design.[52] Both studies relied upon nasopharyngeal cultures to determine the bacterial 
aetiology of the suspected lower respiratory tract infection and included children with 
pertussis and cough duration as brief as 10-days, while outcomes were based upon 
physician’s assessment and not defined fully. Antibiotic courses were for 7-days and 
included erythromycin in one trial[22] and relatively low doses of amoxicillin-clavulanate in 
the other.[53] A recent RCT had a more robust design and found that children treated with 
conventional doses of amoxicillin-clavulanate for 2-weeks had higher rates of cough 
resolution than those receiving placebo (48% versus 16% respectively).[48] However, this 
trial included only 25 subjects in each treatment arm and was conducted in a specialist clinic 
raising the possibility of sample bias towards more severe cases. Importantly, none of the 
studies undertook long-term follow-up to determine recurrence rates following treatment.    
 
The remaining evidence supporting the role of antibiotics was limited to a small number of 
observational studies, many involving children with chronic cough from various causes, 
where controls were absent and cough resolution following antibiotics was not a main 
outcome (Supplementary Table 6). These studies suggested that at least a 2-week course of 
antibiotics active against respiratory bacterial pathogens (H. influenzae, S. pneumoniae,  
M. catarrhalis, S. aureus) found in the lower airways of children with chronic wet or 
productive cough were associated with increased likelihood of cough resolution.[16,24,25] 
However, symptomatic recurrences were common,[16,24,25] occurring in as many as 76% of 
cases, while a poor response to >4-weeks of treatment increased the likelihood of underlying 
bronchiectasis being present.[33]  
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While there was some evidence that antibiotics improved clinical outcomes in children with 
chronic wet or productive cough unrelated to underlying disease and without any specific 
cough pointers, larger RCTs of well characterised children with chronic wet cough recruited 
from multiple centres to reduce sample bias and with prolonged follow-up are needed. The 
lack of comparative studies means important knowledge gaps exist involving the choice of 
antibiotic, the doses to be prescribed, and the treatment duration needed, to optimise the 
clinical response and reduce the risk of recurrent chronic wet cough.   
 
A recent review recommended that until further evidence is available, children with an 
isolated chronic wet cough, lacking symptoms and signs of an underlying disease, and whose 
chest radiograph is normal (or shows only peribronchial changes) should receive 2-4 weeks 
of an oral antibiotic directed against common respiratory bacterial pathogens associated with 
PBB.[21] As most children are too young to expectorate and provide a reliable spontaneous 
or induced sputum specimen, the choice of antibiotic is frequently empirical and determined 
by local antibiotic susceptibility patterns. The antibiotic used most widely is oral amoxicillin-
clavulanate, which is also active against beta-lactamase producing strains of H. influenzae, 
M. catarrhalis and S. aureus, although alternatives such as an oral cephalosporin, 
trimethoprim-sulphamethoxazole or a macrolide may be used when there is a history of 
immediate hypersensitivity to penicillin. This review also recommended that investigations 
for an underlying cause should be undertaken in the small group of children who, despite 
adhering to their treatment, fail the 4-week course of antibiotic therapy.[21,33] 
 
Treatment failure (KQ6) 
There are many causes of chronic wet cough in children, of which PBB is just one.[21] In 
those who fail therapy (Figure), possible reasons are non-adherence and/or other causes of 
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chronic wet cough. These children should be referred for further evaluation and 
investigations recommended for suspected CSLD or bronchiectasis.[54] Intravenous 
antibiotics are likely beneficial in those with persistent endobronchial infection, even without 
CT scan evidence of bronchiectasis,[55] since early intervention to break the ‘vicious cycle’ 
of infection, inflammation and impaired mucociliary clearance might prevent future 
development of bronchiectasis.[56,57] 
 
Recurrent chronic wet cough following successful antibiotic treatment 
(KQ7) 
A prolonged period of observation is required to determine the recurrence rate and only 
limited data were available, all from three retrospective studies[16,24], which were included 
in the systematic review for KQ7. These studies provided little or no evidence for the role of 
prophylactic antibiotics, risk of increased antibiotic resistance following treatment or how 
recurrences of PBB should be managed (Supplementary Table 7).  
 
The first[16] reported that while 51% of 81 children with newly diagnosed PBB were 
completely symptom free after two prolonged (6-8 week) courses of antibiotics, 13% 
required either ≥6 courses of antibiotics or had continuous prophylactic antibiotic for at least 
one winter to control symptoms with another 5% requiring intermittent antibiotic courses and 
still under active review. However this study[16] included children with bronchiectasis and 
used different definition of PBB. The second[24] noted that over a 2-year period only 25% of 
33 patients remained well following their first 6-8 week course of antibiotics, despite all 
achieving complete resolution of their cough symptoms by the 14th day of therapy. 
Moreover, three 10% of these children had three or more recurrences and overall nine (27%) 
received long-term prophylactic antibiotics. Like the first study, the definition of PBB was 
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not the same as that proposed in this taskforce document. Finally, a third retrospective 
study[25] reported complete resolution of symptoms in all but one of 61 children who 
underwent BAL for chronic wet cough followed by >2-week course of oral antibiotics. Of 
these children, 43 (70%) required repeated courses of treatment for recurrent symptoms.  
 
It should be noted there was no systematic approach to starting prophylactic antibiotics, with 
some children beginning these after a single recurrence, while details on antibiotics, repeat 
treatment courses and outcome are scant. Microbiology reporting was incomplete and no 
antibiotic resistance data were presented. Thus crucial knowledge gaps remain on how to best 
manage children with recurrent PBB, how these episodes might be prevented, and the impact 
of long-term antibiotics upon antimicrobial resistance in this patient population.  
 
Subsequent to the Task Force group meeting, the sole published long-term prospective 
follow-up study described a subgroup of children with PBB who subsequently received a 
diagnosis of bronchiectasis.[39] Multivariate logistic regression showed that recurrent 
episodes (>3/year) of PBB (ORadjusted 11.5,95%CI 2.3-56.5, p=0.003) and presence of  
H. influenzae lower airway infection (ORadjusted 7.6, 95%CI 1.5-37.8, p=0.013) were both 
independently associated with bronchiectasis diagnosis within the 2-year follow-up 
period.[39]  
 
Whether symptom duration prior to treatment impacts on clinical outcomes remains unknown 
as the current definition includes everyone with a persistent wet cough, irrespective whether 
it has been present for weeks, months or even years. The risk of recurrence is likely to 
depend upon factors that are difficult to assess, such as the composition of the respiratory 
microbiota, the relevance of airway malacia and/or subtle immune-deficiencies. Whether the 
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approach to initial therapy (ie. length of antibiotic treatment course) influences the risk of 
recurrence is also unknown. Prescribing 2-4 weeks of oral antibiotic therapy targeted at the 
suspected (or cultured) bacterial pathogens has been part of the diagnostic process. Should 
the cough resolve completely some clinicians will cease therapy at this point, while others 
will continue for prolonged periods. The proposed rationale for prolonged antibiotic use is 
that by protecting the airways against the common respiratory bacterial pathogens for an 
extended period allows the airways to recover their integrity and resist reoccurrence. 
However, this practice is unproven at either a mechanistic or clinical level. In addition, 
prolonged antibiotic exposure disrupts resident microbiota (dysbiosis) and contributes to the 
pathoadaption of organisms within the lower airways, including the selection of antibiotic-
resistant strains.[58,59]  
 
Finally, while once-weekly azithromycin halved the rate of pulmonary exacerbations in 
children with either CSLD or bronchiectasis,[60] its role in PBB remains undefined. This is 
especially important in the setting of the global antibiotic resistance crisis from over-
prescribing antibiotics,[61] where, in addition to the concerns stated above, macrolides in 
particular alter the host’s resident microbiome[62] and provide strong selection pressure for 
antibiotic-resistant organisms, leading to increased treatment costs and risk of treatment 
failure.[63,64]  
 
Research priorities 
 Community-based epidemiological studies to generate data that informs our 
understanding of the current incidence and prevalence of chronic cough in the paediatric 
population across several healthcare settings (countries). Such studies need to assess a 
random selection of those reporting chronic cough to more accurately assess the relative 
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contributions of different diagnostic entities.  
 
 Prospective, longitudinal cohort studies of newly-diagnosed children with PBB are 
needed to determine its natural history, including whether those already with early 
bronchiectasis or at risk of developing this complication can be identified.   
   
 Understanding the impaired pathogen clearance mechanisms underlying PBB, including 
host susceptibility factors and if recurrences and disease progression are influenced 
more by the composition of the respiratory microbiota than by individual pathogens. 
This information is critical for identifying susceptible infants and children and 
developing novel treatments and prevention strategies.  
 
  Strengthen the evidence-based diagnostic algorithm for a child with an ‘isolated’ 
chronic wet cough and lacking specific cough pointers to help determine those most 
likely to benefit from antibiotics and when to investigate for an underlying disorder.  
 
 Undertake multicentre RCTs in children with chronic wet cough to help identify the 
antibiotic class, dose and course duration that optimises cough resolution and reduces 
the likelihood of recurrences in children with PBB while still minimising antibiotic 
resistance. 
o Examples might include:    
o Beta-lactam versus trimethoprim-sulphamethoxazole versus macrolide 
antibiotics    
o Higher versus standard dosing (eg. amoxycillin-clavulanate at 90mg/kg/day 
versus 60mg/kg/day) 
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o Extended versus standard antibiotc course duration (eg. 8-weeks versus  
4-weeks versus 2-weeks).   
 Undertake multicentre RCTs in children with recurrent (eg. >3 episodes annually) 
PBB to determine if long-term oral (eg. azithromycin) or inhaled antibiotics reduce 
the risk of further episodes of chronic wet cough and improve long-term outcomes. If 
successful, such studies would need to identify those most likely to benefit, for how 
long antibiotics should be administered and to examine the impact of this treatment 
upon the respiratory microbiome and resistome.  
 
And so, back to the 3-year old boy who received a 2-week course of amoxicillin-clavulanate, 
following which his cough resolved completely. His parents are informed of his diagnosis of 
PBB and counselled that PBB is an endobronchial infection. If a flexible bronchoscopy and 
lavage were undertaken we would likely find common respiratory bacteria and airway 
inflammation. However, at this point in time, we do not really know why PBB occurs in 
some and not in others. While we now understand some of the associations with PBB and 
have found that PBB can recur, we do not know who are more likely to experience 
recurrence or whether an even longer course of antibiotics reduces the chance of having a 
recurrence. Recurrence PBB should be managed with further antibiotic courses and if more 
than 3 episode per year occur, further investigations are likely indicated.   
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Figure Legend  
Possible approach to a child with a chronic (>4-weeks) wet cough. It is not a management 
guideline.  
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Table 
Summary of studies found in the systematic reviews of the key questions.  
 
1st author, 
publication y; 
country 
Setting; 
Study design 
Inclusion and Exc criteria; 
or definitions 
N enrolled, N completed; 
Follow-up length; 
Age 
Main aim(s) of study Relevant 
to KQs 
 
PROSPECTIVE STUDIES 
 
  Findings of the studies related to the KQs are 
in the Supplementary Tables 
Aluoch[65] 
1984, Kenya 
Single centre; 
General OPD, 
cross sectional 
Aged >6y, first attendance with main 
complaint of cough, sputum (>1mo) or 
haemoptysis; 
Exc: NR 
N=601; N with sputum=601; 
median age NR and study included 
adults;  
FU=NR  
Yield of tuberculosis from 
systemic examination of first 
presentation 2 
Asilsoy,[8] 
2008 
Turkey 
Single centre, Paed 
OPD; 
Cohort 
>4w cough; 
Exc: NR 
 
N=108, N completed=108 
FU:NR 
Mean age=8.4 y; range 6-14  
“evaluate children with cough in 
accordance with the 2006 ACCP 
guidelines”[8] 
1, 2, 6 
Baines,[46] 
2014; 
 Australia 
Single centre, Resp 
OPD; exploratory 
& validation 
cohorts 
 
PBB=clinical definition; 
Resolved PBB =previous PBB, but no 
cough at FB 
Exp: PBB=21; Controls=33; 
Respective mean ages= 2.3 & 9.7 y; 
Validation: PBB=36; Controls=11; 
Respective mean age=2.0 and 0.7y   
To evaluate the IL-1 and  
TNF-α/NF-κB pathways and 
mediators in 2 cohorts of PBB and 
control children 
1, 2, 3, 5, 
Chang[66] 
2006 
Australia 
Single centre; Resp 
OPD, 
cross-sectional 
Children undergoing FB without a 
known underlying resp Dx 
N=106; 
Median age=2.6y,  
IQR 5.7 
FU=NR 
 
Compare (a) cough quality 
(wet/dry and brassy/non-brassy) 
to FB findings of secretions and 
tracheomalacia respectively, (b) 
parent's vs clinician's evaluation 
of cough quality (wet/ dry) 
2 
Chang[67] 
2006 
Australia 
Single centre; Resp 
OPD, 
cross-sectional 
Children undergoing FB without a 
known underlying resp Dx 
N=106; 
Median age=2.6y,  
IQR 5.7 
FU=NR 
 
Examine the relationship between 
the amount of secretions seen at 
bronchoscopy with airway 
cellularity and microbiology 
3 
Chang,[47] 
2012; 
Single centre, Resp 
OPD;  
PBB=chronic wet cough, response to 
ABs with resolution of cough within 
Current PBB=61, PBB well=20, 
Controls=21;  
To determine whether BAL levels 
of hBD2, SP-A, and MBL: (a) 1, 2, 3, 5 
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Australia cross-sectional 
 
2w & absence of signs or symptoms of 
other disease; PBB well=previous 
PBB, but no cough when FB done 
FU: NR 
Respective mean age (SD) =2.5y (2.3), 
4.2y (3.0), 2.2y (2.8) 
differed between children with 
current PBB, PBB well, and 
controls; and (b) related with 
airway neutrophilia and infection 
Chang[68] 
2013 
Australia 
Multicentre,  
Resp OPD, 
RCT 
Aged <18y, >4w cough, newly 
referred;  
Exc: known chronic resp illness 
 
N enrolled=270, 
N completed=253 
FU=12mo for Dx, 6mo post Dx; 
Mean=4.5 y, SD=3.7 
RCT to determine if Mx 
according to a standardised 
clinical Mx pathway improves 
clinical outcomes 
2 
Chang[31] 
2015 
Australia 
Multi-centre, Resp 
OPD; 
Cohort 
Aged <18y, >4w cough newly referred 
Exc: chronic respiratory illness 
N of cohort=346,  
N completed=326; 
Follow-up=12mo for Dx,  
6mo post Dx 
Mean age=4.5y, SD 3 
In children newly referred for 
chronic cough, to describe data 
relating to specific cough pointers 
of the 3 most common aetiologies 
1, 2 
Coren[69] 
1998 
England 
Uni-centre; 
General OPD, 
Cross-sectional 
All CT scans undertaken over 12mo.  
Exc: NR 
102 children had 106 CT scans. 
FU=NR; 
Median age=5y (range 7w-15y)  
To determine whether use of 
paediatric chest CT scans was 
appropriate (new Dx and how it 
influenced Mx) 
2 
Darelid[22] 
1993  
Sweden 
3 centres Pediatric 
OPD; 
open RCT 
Aged 0.5-6y, persistent cough >10 
days.  
Exc: pneumonia, allergy, acute otitis 
media, tonsillitis, cardiac disease, 
suspected pertussis 
N cohort=88; 
N completed=87# 
FU=3mo; 
Median age group=13-24mo 
(IQR NR)  
Whether 7 days of erythromycin 
clinically improves  children 0.5-
6y of age with a cough+ >10 days  1, 6 
De Baets[36] 
2012 
Belgium 
Dual-centre; 
Resp OPD, 
Cross-sectional 
“Persistent resp symptoms, productive 
cough, bronchorrhoea and wheezing 
for ≥3mo.” 
Exc: premature,  failure to thrive, CF, 
prolonged intubation, tracheotomy, 
dysmorphic, neurology, cardiac 
problems, or CXR consolidation 
N=124;  
FU=NR; 
Median age=10mo (IQR 7-14)  
Description of results of 
diagnostic investigations in 
children with persistent resp 
symptoms despite regular asthma 
Rx  
2, 3 
Gedik[35], 
2015, Turkey 
Single centre, 
Paediatric or 
Allergy dept; 
Cohort  
Aged <17y, persistent cough >4w.  
Exc: known chronic resp, 
neuromuscular, growth, cardiac 
problems, genetic syndromes, 
prematurity 
 
N=563, N completed=563 
FU:NR 
Mean age=5.4y, SD 3.8 
The evaluation of children with 
chronic cough and aged-based 
aetiological factors 
 
1, 2, 3, 5 
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Gottfard[53] 
1994  
Sweden 
3 centres Pediatric 
OPD; 
DB RCT 
Lower resp tract infection with cough 
>10 days, >11 coughing attacks in 
24hrs. 
Exc: pneumonia, acute otitis media, 
clinical suspicion of pertussis 
N cohort=52; N completed=52 
FU=14 days; Median age=2.6-2.7y 
(IQR NR) 
 
 
“To investigate the 
nasopharyngeal flora of children 
with persistent cough and the 
effects of treatment with amox-
clavulanate” +[53]  
1, 6 
Grissell[49]  
2007; 
Australia 
Single centre, 
Gastro OPD 
non-bronchoscopic 
BAL  
Children undergoing upper GI 
endoscopy, cough questionnaire. 
Excl: neurodevelopmental abn, 
underlying cardioresp dis, primary 
aspiration  
*Group defined on +ve bacterial 
culture not PBB 
69 children; 
10 positive bacterial growth from non-
bronchoscopic BAL, control group 
n=59  
To examine the expression of 
neurokinins, neurotrophins and 
TLRs in the lungs of children. 
5 
Heino[70] 
1990 
Finland 
Single centre, Resp 
OPD;  
cross-sectional 
Chronic productive cough (>3mo) 
unresponsive to oral ABs and oral 
bronchodilators  
N=7;  
Age range 5-11y 
 
Describe ultrastructural nature of 
epithelial damage in respiratory 
symptoms 
2 
Hodge[44] 
2016; 
Australia 
Single centre, Resp 
OPD; 
cross-sectional 
PBB-micro; Controls=no cough and 
FB undertaken for other reasons (e.g. 
stridor); BE=CT scan defined with 
clinical symptoms 
PBB=13, BE=55, controls=13. 
Median ages and IQR: 
PBB=6.5mo (1.6-14) 
BE=22mo (14-33) 
Controls=5.5mo (4-9.9) 
(a) Quantify phagocytosis of 
airway apoptotic cells and NTHi 
by alveolar macrophages in 
children with PBB and BE; (b) 
Determine if phagocytic capacity 
associated with clinical variables, 
and patterns of airway 
inflammation 
1, 3, 5 
Karabel[29] 
2014 
Turkey 
Single centre, Resp 
OPD; 
Cohort 
>4w cough 
Exc: Neuromuscular, cardiac, 
syndromes, resp infection last 4w 
N cohort=270, 
N completed=270; FU=12mo 
Mean age=6.5y, range 7mo-17y 
To determine the aetiology of 
chronic cough in children using 
the ACCP guidelines 
1, 2, 6 
Marchant[4] 
2006 
Australia 
Single centre, Resp 
OPD, 
Cohort 
>3w cough, age <18y and newly 
referred 
Exc: known chronic disease 
 
N cohort=108; 
N completed=103 
FU=12mo; 
Median age=2.6y (IQR 1.2-6.9) 
In children with chronic cough, 
to; (a) evaluate the use of an 
adult-based algorithmic approach 
in the management, (b) describe 
the aetiology  
1, 2, 3, 5, 
6 
Marchant,[45
] 2008; 
Australia 
Single centre, Resp 
OPD;  
cross-sectional 
PBB=chronic wet cough (>3w), BAL 
bacterial culture (≥105 CFU/mL) & 
response to Abs (cough resolved in 
2w); Other aetiologies=other chronic 
PBB=38, other Dx=25, SR=22, 
controls=15; Respective median age 
(IQR): 2.4y (0.9-4.2), 2.6y (1.1, 9.6), 
3.8y (0.9, 6.8), 2.8y (0.6, 9.8) 
To: (a) describe the clinical 
profile, airway cellularity and 
promoters of neutrophilic 
inflammation in BAL fluid of 
1, 2, 3, 5 
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cough aetiologies in cohort;[4] 
Controls=children with stridor without 
chronic cough 
 children with PBB compared to 
children with other aetiologies 
and controls without cough , (b) 
explore selected innate immunity 
signaling receptors, specifically 
TLR-2 and -4  
Marchant[48] 
2012 
Australia 
  
Single centre, 
Paediatric and resp 
OPD; 
DB RCT 
Aged 0.5-18y, doctor observed wet 
cough >3w; 
Exc: chronic lung, cardiac neuro-
development disease, ABs in the last 
2w, acutely unwell 
N cohort=50,  
N completed=47 
FU=2 w 
Mean age=1.8-2.8y, IQR 0.9-5.3 
Efficacy of 2 w of oral amoxi-clav 
(compared with placebo) in 
achieving cough resolution in 
children with chronic wet cough 
1, 3, 5, 6 
Seear[71] 
1997 
Canada 
Single centre, Resp 
OPD, 
Cross-sectional 
Chronic (≥3mo) productive or rattly 
cough, with or without wheezing; 
Controls: children with asthma; Exc: 
known causes of productive cough 
N=81 
N completed=81 
FU:NR 
Mean age=8.4y; range 6-14y 
N controls=60 
In children with chronic 
productive cough, “(a) do such 
diagnostic orphans exist? (b) if so, 
can they be classified in a 
clinically useful manner” 
2 
Usta,[9]  
2014 Turkey 
Single centre, 
paediatric allergy 
OPD; cohort   
Inclusion: NR 
Exc: cardiac or chronic disease, 
prematurity, neuro-development, chest 
wall deformity, smoking, clubbing, if 
spirometry not possible 
N cohort=156, 
N completed=156, 
FU=max 18mo for Dx,  
NR post Dx;  
Mean age=8.4y; SD 2.6  
“Evaluate assessment and Mx of 
chronic cough in children 
according to the British Thoracic 
Society guidelines” 
1, 2, 6 
Van der 
Gast,[42] 
2014; 
USA and 
Australia 
Multi-centre, Resp 
OPD;  
cross-sectional 
PBB=clinical def;  
BE=Dx on CT scan; 
CF=positive sweat test 
PBB=12, BE=19; CF=25; Respective 
mean (SD) age: 8.9y (4.7), 2.3y (1.7), 
12.5y (3.5) 
 
To compare: (a) the core and 
satellite microbiota in cohorts of 
children with different diseases; 
(b) the respiratory meta-
communities in PBB and 
paediatric and adult CF and BE 
cases 
1, 2, 3 
Wurzel[38] 
2014 
Australia 
Single centre, Resp 
OPD, 
cross-sectional 
Children undergoing FB. Children 
categorised into wet cough, dry cough, 
no cough groups; 
Exc: CF 
Wet cough n=143 
Median age=26mo (IQR 15-60) 
Dry cough n=18 
Median age=66mo (IQR 31-159) 
FU=NR  
Examine the relationships 
between cough nature, lower 
airway infection and severity of 
neutrophilic airway inflammation 
2, 3, 4, 5 
Wurzel[30] 
2014; 
Single centre, Resp 
OPD;  
PBB=clinical def; Controls=chronic 
resp symptoms, but not PBB or CSLD 
PBB=104, Controls=21; 
Respective median age (IQR)  
To provide extensive clinical, 
laboratory, and BAL 1, 2 
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Australia cross-sectional 19mo (12-30), and 20mo (8-63)  characterisation of PBB 
Wurzel,[41] 
2014; 
Australia 
Single centre, Resp 
OPD;  
cross-sectional 
PBB=clinical def;  
BE=Dx on CT scan 
PBB=159, BE=112; 
Median (IQR) age: PBB with 
AdV=17mo (12-22), PBB without 
AdV=26mo (15-56) 
To identify: (a) the prevalence of 
AdV; (b) diversity of genotypes 
and species (c) whether presence 
of AdV increased the odds of 
bacterial coinfection 
1, 3, 4 
 
RETROSPECTIVE STUDIES 
 
  
 
Chang[51] 
2002, 
Australia 
Resp OPD,  
Chart review 
CSLD (>4mo wet cough) Indigenous 
children 
n=65; (n=33 bronchoscopy) 
Med age=3.8y 
(*n=28 of 33 radiological BE) 
Children prospectively identified 
and charts reviewed 
retrospectively to describe airway 
abnormalities and relate these to 
chest HRCT scans 
5 
Donnelly[16] 
2007, 
England 
Single centre, Resp 
OPD; random 
review of clinic 
letters 
“Persistent, wet cough present for  
1mo that resolves with appropriate AB 
treatment” 
N=81; 
Median age=3.8y (range 0.4-14.8); 
FU=NR 
 
To present “results of a 
retrospective review of outcomes 
in 81 randomly selected patients 
diagnosed with PBB” 
1, 3, 6, 7 
Douros[34] 
2011, Greece 
Allergy-Resp OPD, 
Chart review 
Chronic (>6w) wet cough with FB 
undertaken for criteria*; 
Exc: CF, immuno-deficiency, 
neuromuscular disorder, aspiration 
93; 
FU=NR 
Mean age=5.8y, SD 3.6 
In children with chronic wet 
cough: (a) Comparison of chest 
CT and FB in detecting airway 
abnormalities and (b) explore 
radiological and FB/BAL 
associations 
2, 3, 5 
Goyal[33] 
2014 
Australia 
Single centre; 
Resp OPD, 
Chart and CT scan 
review 
Chronic wet cough (>4w) and having 
completed >4w of oral ABs directed 
against likely resp bacteria 
Exc: asthma, CF, known BE or CT 
scans ordered by oncology, surgical, 
ICU, trauma services   
N=144 (106 with BE); 
FU=NR; 
Median age=4.7y (range 0.3-17)  
“To determine whether a child 
with chronic wet cough and poor 
response to at least 4w of oral 
ABs is more likely to have BE” 
(radiologically defined) 
2, 6 
Kompare[25] 
2011, 
USA 
Single centre, Resp 
& allergy OPD  
Bronchoscopy 
database review 
Cough, wheeze or noisy breathing of 
>1mo without other diagnoses, 
infected BAL (≥104 cfu/ml) and 
response to ≥2w ABs  
70 in cohort (cough=51) 
Summary age NR; 
FU=NR 
 
Review all infected BAL of 
children aged <5y with cough, 
wheeze or noisy breathing of >1 
mo without other diagnoses, to 
determine if PBB present  
1, 2, 3, 5, 
6 
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Lim[72] 2012 
England 
Single centre; 
Resp OPD; 
Chart review 
Chronic wet cough (>8w) attending 
clinic over a 12mo period 
Exc: CF 
96 children with wet cough, 66 tested; 
All >2y (summary NR); 
FU=18mo 
Prevalence of specific antibody 
deficiency in children with 
chronic wet cough”[72] 
2 
Narang,[40] 
2014; 
England 
Paediatric and Resp 
OPD; 50 
consecutive notes 
Suspected PBB (ND) 50; Median age=2.9y  
(IQR 1.7-4.4) 
Review BAL and CXR results, 
and assess the bacterial 
distribution across lung lobes  
1, 2, 3 
Priftis,[28] 
2013;  
Greece and 
England  
Resp OPD, 
Dual centre 
Chart review 
Children with chronic cough 
suspicious of PBB who had FB to 
confirm diagnosis  
Greece=18 
England=39; Median age=4.8y (range 
0.9-14.4) 
 
To (a) determine specific 
serotypes of Spn and NTHi in 
BAL samples; (b) compare Spn 
serotypes between the 2 countries 
and Spn vaccination  
1, 2, 3 
Pritchard[24] 
2014, 
England 
Single centre, 
Paediatric or Resp 
OPD  
AB responsive wet cough confirmed 
by a positive BAL culture (undefined) 
43 (+1 lost to FU);  
Median age=2.7y (IQR 1.5-4); 
FU=11.3mo (IQR 8.3–14.7) 
Review of outcomes for children 
with AB responsive wet cough 
with positive BAL culture 
1, 2, 3, 6, 
7 
Rother[73] 
2015, 
Germany 
Single centre, 
tertiary hospital; 
Chart review 
NR with respect to key question. 
Children with an established diagnosis 
of asthma, PCD, PBB, acute 
bronchitis, CF or pneumonia. 
18 children with PBB “To develop and test a 
questionnaire-based and data 
mining-supported tool providing 
diagnostic support for selected 
pulmonary diseases” 
1 
Smith[13] 
1985, USA 
Resp OPD, 
Chart review 
Presence of chronic bronchitis by FB 
evaluation.  
Exc: CF or other abnormality that 
could contribute to chronic bronchitis 
20, 
FU=NR; 
Mean age=5.7y (range 0.5-15) 
To investigate clinical, allergic, 
immunological and physiological 
characteristics of children with 
chronic bronchitis 
1, 6 
Thomson[74] 
2002, 
Australia 
Resp OPD,  
Chart review 
Chronic cough >4w n=49 
Med age=39mo (range 4mo-14y) 
Determine (i) the referring and 
final diagnosis; and (ii) the extent 
of the use of medications (asthma, 
GOR, antibiotics) prior to referral, 
and the side effects encountered 
in children referred over a 12mo 
period to paediatric respiratory 
physicians for persistent cough  
 
Wang,[23] 
2015; China 
Single centre, 
Hospitalised 
children in 
children’s hospital, 
Chronic cough (>4w) without acute 
lower resp infection and no response to 
conventional Rx.  
Exc: heart disease, immune-deficiency, 
66 with wet cough, of whom 50 had 
PBB; 
median age=10mo; (5.8–14#) 
To describe the clinical 
characteristics children aged  
<3y with PBB  1, 2, 3, 5 
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unclear how 
children were 
identified 
pulmonary or bronchus dysplasia, 
neuro-muscular disease, foreign body 
aspiration 
Zgherea[37] 
2012, USA 
Single centre, Resp 
OPD,  
Chart review 
Primary symptom of chronic (>4w) 
wet cough who had FB.  
Exc: CF, PCD, immunodeficiency, 
aspiration, asthma, genetic, known 
airway or neuro-muscular disorders 
N=197,  
FU=NR 
Mean=NR  
< 3y:55%; 3-7y:36%; >7 y: 9% 
“Determine the frequency of 
lower respiratory tract bacterial 
infections in children with chronic 
wet cough and to analyze the 
bronchoscopic findings” 
2, 3, 5 
 
AB=antibiotics; Abn=abnormality; ACCP=American College of Chest Physicians; AdV=adenovirus; Amox-clav=amoxicillin-clavulanate; 
BAL=bronchoalveolar lavage; BE=bronchiectasis; CF=cystic fibrosis; CFU=colony-forming unit; Clarithro=clarithromycin; CSLD;=chronic 
suppurative lung disease; CT=chest computed tomography; CXR=chest radiograph; d=days; DB=double blinded; Def=definition; Dis=disease; 
Dx=diagnosis; Exc=exclusion criteria; Exp=exploratory; FB=flexible bronchoscopy; FU=follow-up; mo=months; Gastro=gastroenterology; 
GI=gastrointestinal; GOR=gastro-oesophageal reflux; Hi=Haemophilus influenzae; HRCT=high-resolution computed tomography; ICS=inhaled 
corticosteroids; ICU=intensive care unit; IL=interleukin; IQR=interquartile range; KQs=key questions; MBL=mannose binding ligand; Mcat= 
Moraxella catarrhalis; Micro=microbiology; mo=months; Mx=management; N=number; ND=not defined; NF=nuclear factor; NR=not reported; 
NTHi=non-typeable Haemophilus influenzae; OPD=outpatients department; PBB=protracted bacterial bronchitis; PCD=primary ciliary 
dyskinesia; RCT=randomized control trial; Resp=Respiratory; Rx=treatment; Sa=Staphylococcus aureus; SD=standard deviation; 
SPA=surfactant protein A; Spn=Streptococcus pneumoniae; SR=spontaneous resolution; TLRs=toll-like receptors; TNF=tumour necrosis factor; 
w=weeks; y=year 
 
*Not all children in cohort had PBB i.e. some had bronchiectasis 
#Unclear what these figures refer to as figure in the table differed from the text 
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Box 
*Specific cough pointers[5,6,75] are:  
Symptoms: chest pain, history suggestive of inhaled foreign body, dyspnoea, exertional 
dyspnoea, haemoptysis, failure to thrive, feeding difficulties (including 
choking/vomiting), cardiac or neurodevelopmental abnormalities, recurrent sino-
pulmonary infections, immunodeficiency, epidemiological risk factors for exposure to 
tuberculosis.  
Signs: respiratory distress, digital clubbing, chest wall deformity, auscultatory crackles. 
Tests: Chest radiographic changes (other than perihilar changes), lung function 
abnormalities. 
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Chronic (>4-weeks duration) wet or productive cough
Identify any specific cough pointers,* perform 
chest radiograph and (if possible) spirometry
Specific cough pointers present
Investigate accordingly
Specific Pointers Absent
Specific disorder diagnosed No Specific diagnosis
Treatment based on diagnosis
Attempt sputum culture
Trial treatment for PBB
Wet cough persists
(check adherence)
Wet cough resolved
Diagnose PBB
Recurrence No recurrenceInvestigate for an underlying cause
Further antibiotic course
Consider further investigations* See Box.
